GlassScriptPhysician profile
Cynthia Pham
NPI 1063623080
$2,720.14
in general payments reported to CMS, 2019-2025
26 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $298 · 2021: $507 · 2022: $320 · 2023: $437 · 2024: $358 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307 · Education: $54.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.98 |
| Education | $54.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,089.02 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $219.56 | 2019-2025 | Otezla, Repatha, Otezla |
| Genzyme Corporation | $208.50 | 2022-2025 | |
| Optinose US, INC. | $162.23 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.18 | 2023-2025 | |
| Glaxosmithkline, LLC. | $142.76 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $121.59 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $70.01 | 2022-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $66.85 | 2023-2025 | Ozempic, Rybelsus |
| Greer Laboratories, INC. | $60.70 | 2023-2024 | Oralair |
| Abbvie INC. | $54.96 | 2023 | |
| Pfizer INC. | $43.11 | 2024 | |
| Sumitomo Pharma America, INC. | $39.10 | 2024-2025 | Gemtesa |
| Inspire Medical Systems, INC. | $37.63 | 2023 | Inspire |
| Paratek Pharmaceuticals, INC. | $36.86 | 2025 | Nuzyra, Xhance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.63 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $29.20 | 2019-2023 | |
| Henry Schein, INC. | $26.56 | 2025 | |
| Medtronic, INC. | $21.27 | 2024 | Propel |
| Amniox Medical, INC. | $20.50 | 2020 | |
| Seqirus USA INC | $18.37 | 2025 | Flucelvax |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.82 | 2025 | Jardiance |
| Dexcom, INC. | $16.18 | 2023 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $15.58 | 2021 | |
| Exact Sciences Corporation | $14.51 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.